Page last updated: 2024-12-08

(2-benzoylethyl)trimethylammonium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(2-Benzoylethyl)trimethylammonium, also known as **BTMA**, is a quaternary ammonium compound. It's not a naturally occurring molecule but a synthetic compound with a specific structure:

* **Trimethylammonium group:** This is a positively charged nitrogen atom attached to three methyl groups.
* **Benzoylethyl group:** This is a chain with a benzoyl group (a benzene ring with a carbonyl group attached) and an ethyl group.

**Importance for Research:**

BTMA has gained attention in research due to its **potential biological activities and applications**. Here's a breakdown:

1. **Antimicrobial properties:** Studies have shown that BTMA exhibits antimicrobial activity against various bacteria and fungi. This property makes it potentially valuable for developing new antibacterial and antifungal agents.

2. **Anti-inflammatory effects:** Some research suggests that BTMA might possess anti-inflammatory properties, which could be relevant for treating inflammatory diseases.

3. **Pharmaceutical development:** BTMA's structure and its potential biological activities make it an attractive candidate for developing novel pharmaceuticals. Researchers are exploring its applications in drug delivery, specifically for targeting specific tissues or organs.

4. **Material science:** BTMA can act as a surfactant, meaning it can reduce surface tension. This property makes it useful in creating new materials and coatings with specific properties, such as improved water repellency or adhesion.

5. **Catalysis:** BTMA can be used as a catalyst in organic reactions, potentially leading to new synthetic pathways and efficient processes.

**Overall:** BTMA remains an area of ongoing research, and its true potential in various fields is still being explored. Its unique properties make it a promising compound for developing new solutions in healthcare, material science, and other areas.

**Important Note:** While there's potential, it's crucial to remember that these applications are still under investigation. More research is needed to fully understand the benefits and risks associated with BTMA before it can be widely implemented.

(2-benzoylethyl)trimethylammonium: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID152676
SCHEMBL ID10256392
MeSH IDM0067506

Synonyms (7)

Synonym
NCIOPEN2_008256 ,
(2-benzoylethyl)trimethylammonium
trimethyl-(3-oxo-3-phenylpropyl)azanium
benzenepropanaminium, n,n,n-trimethyl-gamma-oxo-
SCHEMBL10256392
DTXSID00179240
trimethyl-(3-oxo-3-phenyl-propyl)azanium
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (72.73)18.7374
1990's2 (18.18)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]